- Proceeds will be used to launch Jornay PM
- Jornay PM is a novel formulation of methylphenidate which is taken in the evening
- Trials demonstrated improvement in the severity... read more
The U.S. Food and Drug Administration announced on 8/22/18 that it has approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the... read more
Kaleido Biosciences, a clinical-stage healthcare company leading the development of novel chemistries that drive functions of the microbiome organ, today... read more
Gynesonics, a women’s... read more
SkinBio Therapeutics Provided a Business Update on 8/16/18
Using a third party manufacturer, the company has now achieved significant manufacturing scale up with, with no... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,